Last reviewed · How we verify
NCT03122496
Immunotherapy and Stereotactic Body Radiotherapy (SBRT) for Metastatic Anaplastic Thyroid Cancer
Phase 1 trial testing durvalumab in Metastatic Anaplastic Thyroid Cancer in 13 participants. Completed in 3 June 2022.
3 June 2022
Quick facts
| Lead sponsor | Memorial Sloan Kettering Cancer Center |
|---|---|
| Phase | Phase 1 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 13 |
| Start date | 25 April 2017 |
| Primary completion | 3 June 2022 |
| Estimated completion | 3 June 2022 |
| Sites | 8 locations across United States |
Drugs / interventions tested
- durvalumab — full drug profile →
- tremelimumab (TREMELIMUMAB) — full drug profile →
- Stereotactic Body Radiotherapy (SBRT) — full drug profile →
Conditions studied
- Metastatic Anaplastic Thyroid Cancer — all drugs for Metastatic Anaplastic Thyroid Cancer →
Sponsor
Memorial Sloan Kettering Cancer Center — full company profile →
Who can join
18 and older, any sex, with Metastatic Anaplastic Thyroid Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this study is to test the safety of durvalumab (MEDI4736) and tremelimumab in combination with radiation therapy and find out what effects, if any, this combination has on people, and whether it improves overall survival.
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
-
2021 American Thyroid Association Guidelines for Management of Patients with Anaplastic Thyroid Cancer.
Bible KC, Kebebew E, Brierley J, Brito JP, et al · · 2021 · cited 464× · PMID 33728999 · DOI 10.1089/thy.2020.0944 -
Targeted Therapy for Advanced Thyroid Cancer: Kinase Inhibitors and Beyond.
Cabanillas ME, Ryder M, Jimenez C. · · 2019 · cited 247× · PMID 31322645 · DOI 10.1210/er.2019-00007 -
Therapeutic advances in anaplastic thyroid cancer: a current perspective.
Saini S, Tulla K, Maker AV, Burman KD, et al · · 2018 · cited 168× · PMID 30352606 · DOI 10.1186/s12943-018-0903-0 -
Characterizing dedifferentiation of thyroid cancer by integrated analysis.
Luo H, Xia X, Kim GD, Liu Y, et al · · 2021 · cited 136× · PMID 34321197 · DOI 10.1126/sciadv.abf3657 -
Updates on the Management of Thyroid Cancer.
Araque KA, Gubbi S, Klubo-Gwiezdzinska J. · · 2020 · cited 115× · PMID 32040962 · DOI 10.1055/a-1089-7870 -
Anaplastic Thyroid Carcinoma: An Update.
Jannin A, Escande A, Al Ghuzlan A, Blanchard P, et al · · 2022 · cited 110× · PMID 35205809 · DOI 10.3390/cancers14041061 -
The Immune Landscape of Thyroid Cancer in the Context of Immune Checkpoint Inhibition.
Varricchi G, Loffredo S, Marone G, Modestino L, et al · · 2019 · cited 78× · PMID 31412566 · DOI 10.3390/ijms20163934 -
Recent advances in the management of anaplastic thyroid cancer.
De Leo S, Trevisan M, Fugazzola L. · · 2020 · cited 67× · PMID 33292371 · DOI 10.1186/s13044-020-00091-w
Verify or expand the search:
- PubMed search for NCT03122496
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of durvalumab
Trials testing the same drug.
- NCT06694454 — Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immun · Phase 1, PHASE2 · not yet recruiting
- NCT05924880 — A Phase 3b, Open-label, Multi-center Study on Durvalumab in Combination With Gemcitabine-based Chemotherapy as 1L Treatm · Phase 3 · completed
- NCT05683977 — A French Real-life Study: EvaluatioN of durvALumab Utilization and Effectiveness for First Line Extensive Stage Small Ce · active not recruiting
- NCT05298423 — Study of Pembrolizumab/Vibostolimab (MK-7684A) in Combination With Concurrent Chemoradiotherapy Followed by Pembrolizuma · Phase 3 · active not recruiting
- NCT05043090 — Savolitinib Plus Durvalumab Versus Sunitinib and Durvalumab Monotherapy in MET-Driven, Unresectable and Locally Advanced · Phase 3 · active not recruiting
Other Memorial Sloan Kettering Cancer Center trials
Trials by the same sponsor.
- NCT07566377 — Cord Blood Transplantation in Children and Young Adults With Blood Cancer · Phase 2 · recruiting
- NCT07507643 — A Study of Methylprednisolone in People Having Liver Surgery · Phase 3 · recruiting
- NCT07483307 — A Study of the Impact of Endocrine Therapy on Surgical Outcomes in People With Breast Cancer · Phase 2 · recruiting
- NCT07459673 — HERizon-Breast: A ctDNA-Guided Adaptive Study of Sequential Anti-HER2 Therapies and CNS Prophylaxis to Induce Long-Term · Phase 2 · recruiting
- NCT07449195 — A Study Comparing Two Optical Coherence Tomography Devices in People With Ocular Tumors · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03122496 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Memorial Sloan Kettering Cancer Center
- Last refreshed: 8 June 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03122496.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing